DOCSLIB.ORG

Information to Users

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Information to Users The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in. this copy for an additional charge. Contact UMI directly to order. UMI A Bell & Howell Information Company 300 North Zeeb Road. Ann Arbor. M148106· 1346 USA 313/761-4700 800:521·0600 THE DIRECT AND MODULATORY ANTINOCICEPTIVE ACTIONS OF ENDOGENOUS AND EXOGENOUS OPIOID DELTA AGONISTS by TODD WILLIAM VANDERAH A Dissertation Submitted to the Faculty of the COMMITTEE ON PHARMACOLOGY AND TOXICOLOGY In Partial Fulfillment of the Requirements For the Degree of DOCTOR OF PHILOSOPHY In the Graduate College THE UNIVERSITY OF ARIZONA 1 995 UMI Number: 9534695 OMI Microform 9534695 Copyright 1995, by OMI Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United states Code. UMI 300 North Zeeb Road Ann Arbor, MI 48103 2 THE UNIVERSITY OF ARIZONA GRADUATE COLLEGE As members of the Final Examination Committee, we certify that we have read the dissertation prepared by--------------------------------------- Todd W. Vanderah entitled The Direct and Modulatory Antinociceptive Actions of Endogenous and Exogenous Opioid Delta Agonists. and recommend that it be accepted as fulfilling the dissertation Doctor of Philosophy Date MMc,t-l 2.3 I (6j 1 '5 Date t?LJ ;2 7, 11<1;- Date I ~f!f-5.-ate 1/14$ 2tf, (1'15 nate ' Final approval and acceptance of this dissertation is contingent upon the candidate's submission of the final copy of the dissertation to the Graduate College. I have read this dissertation prepared under my that it be accepted as fulfilling the dissertation 3 STATEMENT BY AUTHOR This dissertation has been submitted in partial fulfillment of the requirements for an advanced degree at the University of Arizona and is deposited in the University Library to be made available to borrowers under rules of the Library. Brief quotations from this dissertation are allowable without special permission, provided that accurate acknowledgment of source is made. Requests for permission for extended quotation from or reproduction of this manuscript in whole or in part may be granted by the head of the major department or the Dean of the Graduate College when in his or her judgement the proposed use of the material is in the interests of scholarship. In all other instances, however, permission must be obtained from the author. SIGNED:~~ 4 ACKNOWLEDGEMENTS I would like to first acknowledge my parents Jim and Linda Vanderah for their support throughout my college education and for teaching me how to be responsible in accomplishing my goals. I am grateful to my grandfather, Roger O'Toole, who has continually enlightened me and stimulated my desire to learn more about the world around us. I would also like to thank my brother, Tony and my sisters Kari and Nicole for encouraging me to continue my education. I would like to especially acknowledge Dr. Frank Porreca for his guidance and support. Dr. Porreca has been nothing less than a father to me, setting an example of what I can only hope to achieve in the future. His brilliance in science and teaching is something I will cherish throughout my career. I would like to extend my appreciation to both Dr. Porreca and his wife, Gabriella, who have been extremely kind and generous to me and my family. I would like·to thank Dr. Yamamura for his leadership and assistance in the field of molecular pharmacology, as well as for helping me receive my first National Institute of Health fellowship. Dr. Yamamura has given me continual and strong encouragement in my school and experimental studies. A sincere thanks is in order for my other committee members, including Dr. Roeske, Dr. Laird and Dr. Lai, for their input and assistance in helping me achieve my doctorate degree. Lastly, I would like to thank numerous friends and family for helping me in my studies, experiments and for support. First, I would like to thank Drs. Robert Horvath, Ken Wild, Antonia Mattia, Qi Jiang, as well as Pam Peterson, Kent Menkens, Rob Bernstein and Ed Bilsky for their help in my experiments for this dissertation. I would also like to thank several other friends that have helped make life during graduate school bearable including, Nick Perrotta, Mike Nichols, Carl Kovelowski, Wanda Hauglum, Russ Ingersoll, Steve Stratton, Tom Ziegler, Mike Ossipov, John McCormick, Chuck Bian, Kathy Dillon, Kim Mayfield, Tracy Crook, Peg Davis, Rebecca Craft, John Murphy, Roland Cooper, Pierre-Louis LIeu, Sue Maxwell, Kathy Lee, Vanna Santoro, Eva Varga, Ichiro Sora, Richard Knapp, Ewa Malatynska, Jeremy Richman, Irene De Leon, Elizabeth Babin, Terri Vorholzer, Anita Russell, Rita Wedell, Jane Ageton, Karla Hayes and Sandy Sledge. I would also like to thank the support relatives gave me including Dr. John Jansheski and his wife Andree, Gloria Felice, Randy Gingerelli and Mark Jansheski. A very special thanks is in order for those who have helped in preparing and proof-reading this dissertation including Dr. Porreca, Sue Waite, Gina Jansheski, Mike Nichols, Ed Bilsky and Dr. Ossipov. 5 DEDICATION I would like to dedicate this dissertation to my wonderful wife, Gina Jansheski, and my beautiful children, Jordan, Jared and Ryan. My wife and children have continually supported and encouraged me throughout my college career. Although there have been times were I have been extremely busy at work, my wife and family understood and never discouraged me from completing my degree. Over the past four years my family has done more for me than I can ask for in a lifetime. Therefore, it is only proper that I dedicate this dissertation to them. 6 TABLE OF CONTENTS Page LIST OF ILLUSTRATIONS ................................. 9 LIST OF TABLE ............•.......................... 16 ABSTRACT ..........•..•............................ 17 INTRODUCTION . • . • . • . 19 Background ...•....•.....•...................... 1 9 Nociception and Pain Pathways ........•........•. 20 Opiates .................................... 25 Pain and the Medicinal Use of Opiates . 26 Opioid Receptors and Endogenous Opioids . .. 28 Endogenous Opioids and Stress . 36 Cloning and Molecular Mechanisms of Opioid Receptors .. 38 Delta Opioid Receptors and Their Relationship to Pain .... 53 Evidence for Opioid Delta Receptor Subtypes . .. 60 Modulatory Effects on Mu Agonists . 67 Hypothesis of the Dissertation . 71 METHODS ........................................... 75 Animals ........................................ 75 Chemicals ....................................... 75 Antisera ........................................ 76 Injection Techniques ............................... 77 Intracerebroventricular Injections . 77 Spinal Injections . • • . 77 Subcutaneous and Intraperitoneal Injections . .. 77 7 Intraplantar Injections .......................... 78 Tail-Flick Assay . 78 Evaluation of Hyperalgesia ........................... 79 Cold-Water Swim-Stress ............................. 80 Cold-Water Swim-Stress Modulation .................... 80 Experimental Procedures ............................. 81 Agonist/Antagonist Studies ...................... 81 Administration of Oligodeoxynucleotides . .. 85 Tolerance and Cross-Tolerance Studies . 87 Body Temperature . 89 Statistics ....................................... 90 Cloning of an Orphan Receptor ........................ 90 Expression and Characterization of the Orphan Receptor . .. 93 Delta Receptor Subtype Studies Results ......................................... 95 Summary ...................................... 101 Cold-Water Swim-Stress Studies Results . 1 06 Summary ...................................... 1 33 Cold-Water Swim-Stress Modulation Studies Results . 141 Summary ... .. 1 50 8 Delta Receptor Modulation Studies in
Load more

Recommended publications
  • 2.0 Synopsis
    Hydrocodone/Acetaminophen Extended Release Tablets M12-807 Abbreviated Clinical Study Report R&D/11/661 2.0 Synopsis Abbott Laboratories Individual Study Table Referring (For National Authority to Part of Dossier: Use Only) Name of Study Drug: Volume: Hydrocodone/Acetaminophen Extended Release Page: Name of Active Ingredient: Hydrocodone 10 mg/ Acetaminophen 650 mg Extended Release Title of Study: A Phase 2, Randomized Withdrawal Study of the Analgesic Efficacy and Safety of Hydrocodone/Acetaminophen Extended Release Compared to Placebo in Subjects with Chronic Low Back Pain Coordinating Investigator: Study Sites: Seventeen investigative sites in the United States Publications: None Studied Period (Years): Phase of Development: 2 First Subject First Visit: 22 June 2011 Last Subject Last Visit: 28 October 2011 Objectives: The primary objective of this study was to compare the analgesic efficacy and safety of 1 tablet of hydrocodone/acetaminophen extended release 10 mg/650 mg administered twice daily over 2 weeks to placebo in subjects with moderate to moderately severe chronic low back pain (CLBP). A secondary objective of this study was to explore the population pharmacokinetics of hydrocodone and acetaminophen resulting from administration of hydrocodone/acetaminophen extended release 10 mg/650 mg tablets. Methodology: This Phase 2, multicenter, double-blind (DB), placebo-controlled, randomized withdrawal study compared the analgesic efficacy and safety of 1 tablet hydrocodone/acetaminophen extended release 10 mg/650 mg to placebo in subjects with moderate to moderately severe CLBP. Subjects met pre-defined criteria at the conclusion of the Open-Label (OL) Titration Period to proceed to randomization into the DB Maintenance Period of the study.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,492.445 B2 Bazhina Et Al
    USOO9492445B2 (12) United States Patent (10) Patent No.: US 9,492.445 B2 Bazhina et al. (45) Date of Patent: *Nov. 15, 2016 (54) PERIPHERAL OPIOID RECEPTOR (58) Field of Classification Search ANTAGONSTS AND USES THEREOF USPC .................................................. 514/282, 289 See application file for complete search history. (71) Applicant: Wyeth LLC, Madison, NJ (US) (56) References Cited (72) Inventors: Nataliya Bazhina, Tappan, NY (US); U.S. PATENT DOCUMENTS George Joseph Donato, III, Swarthmore, PA (US); Steven R. 3,714,159 A 1/1973 Janssen et al. Fabian, Barnegat, NJ (US); John 3,723.440 A 3, 1973 Freter et al. 3,854,480 A 12/1974 Zaffaroni Lokhnauth, Fair Lawn, NJ (US); 3,884,916 A 5, 1975 Janssen et al. Sreenivasulu Megati, New City, NY 3,937,801 A 2/1976 Lippmann (US); Charles Melucci, Highland Mills, 3.996,214 A 12/1976 Dajani et al. NY (US); Christian Ofslager, 4.012,393 A 3, 1977 Markos et al. 4,013,668 A 3, 1977 Adelstein et al. Newburgh, NY (US); Niketa Patel, 4,025,652 A 5, 1977 Diamond et al. Lincoln Park, NJ (US); Galen 4,060.635 A 11/1977 Diamond et al. Radebaugh, Chester, NJ (US); Syed M. 4,066,654 A 1/1978 Adelstein et al. Shah, East Hanover, NJ (US); Jan 4,069,223. A 1/1978 Adelstein Szeliga, Croton On Hudson, NY (US); 4,072,686 A 2f1978 Adelstein et al. Huyi Zhang, Garnerville, NY (US); (Continued) Tianmin Zhu, Monroe, NY (US) FOREIGN PATENT DOCUMENTS (73) Assignee: Wyeth, LLC, Madison, NJ (US) AU 610 561 B2 8, 1988 (*) Notice: Subject to any disclaimer, the term of this AU T58416 B2 3, 2003 patent is extended or adjusted under 35 (Continued) U.S.C.
    [Show full text]
  • Enkephalin Degradation in Serum of Patients with Inflammatory Bowel Diseases
    Pharmacological Reports 71 (2019) 42–47 Contents lists available at ScienceDirect Pharmacological Reports journal homepage: www.elsevier.com/locate/pharep Original article Enkephalin degradation in serum of patients with inflammatory bowel diseases a, a b Beata Wilenska *, Dagmara Tymecka , Marcin Włodarczyk , b c Aleksandra Sobolewska-Włodarczyk , Maria Wisniewska-Jarosinska , d e b a,d, Jolanta Dyniewicz , Árpád Somogyi , Jakub Fichna , Aleksandra Misicka * a Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Warszawa, Poland b Department of Biochemistry, Medical University of Lodz, Łódz, Poland c Department of Gastroenterology, Medical University of Lodz, Łódz, Poland d Department of Neuropeptides, Mossakowski Medical Research Centre Polish Academy of Science, Warszawa, Poland e Campus Chemical Instrumentation Centre (CCIC), The Ohio State University, Columbus, OH, USA A R T I C L E I N F O A B S T R A C T Article history: Background: Inflammatory bowel diseases (IBD) are a group of chronic and recurrent gastrointestinal Received 18 April 2018 disorders that are difficult to control. Recently, a new IBD therapy based on the targeting of the Received in revised form 10 June 2018 endogenous opioid system has been proposed. Consequently, due to the fact that endogenous Accepted 1 August 2018 enkephalins have an anti-inflammatory effect, we aimed at investigating the degradation of serum Available online 2 August 2018 enkephalin (Met- and Leu-enkephalin) in patients with IBD. Methods: Enkephalin degradation in serum of patients with IBD was characterized using mass Keywords: spectrometry methods. Calculated half-life (T1/2) of enkephalins were compared and correlated with the Inflammatory bowel diseases disease type and gender of the patients.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Mu-0Pio:Id Receptor Is Involved in P Endorphin- Induced Feeding in Goldfish
    Peptides, Vol. 17, No. 3, pp. 421-424, 1996 Copyright 0 1996 Elsevier Science Inc. Printed in the USA. All rights reserved 0196-9781196 $15.00 + .@I PIISO196-9781(96)00006-X Mu-0pio:id Receptor Is Involved in P_Endorphin- Induced Feeding in Goldfish NURIA DE PEDRO,’ MARiA VIRTUDES &PEDES, MA&A JESrjS DELGADO AND MERCEDES ALONSO-BEDATE Departamento de Biologia Animal II (Fisiologfa Animal), Facultad de Ciencias Biolbgicas, Universidad Complutense, 28040 Madrid, Spain Received 7 September 1995 DE PEDRO, N., M. V. Cl%PEDES, M. J. DELGADO AND M. ALONSO-BEDATE. Mu-opioid receptor is involved in p- endorphin-inducea'feeding in goldjsh. PEPTIDES 17( 3) 421-424, 1996.-The present study evaluated the central effects of selective opioid receptor subtype agonists and antagonists on food intake in satiated goldfish. Significant increases in feeding behavior occurred .m goldfish injected with P-endorphin, the kappa agonist, U-50488, the delta agonist, [D-Pen’,D-Pen5]enkephalin (DPEN), and the mu agonist, [o-Ala’,N-Me-Phe4,Gly5-ollenkephalin (DAMGO). On the other hand, the different receptor antagonists used: nor-binaltorphamine (nor-BNI) for kappa, 7-benzidilidenenaltrexone (BNTX) for delta,, naltriben for delta,, @imaltrexamine (P-FNA) for mu, and naloxonazine for mu,, by themselves, did not modify ingestion or slightly reduced it. The feeding stimulation by P-endorphin was antagonized by P-FNA and naloxonazine, but not by nor-BNI, BNTX, or naltriben. These data indicate that the mu-opioid receptor is involved in the modulation of the feeding behavior in goldfish. P-Endorphin Food intake Goldfish Opioid receptors Opioid antagonists Mu receptor Delta receptor Kappa receptor THE role of the endogenous opioid system in the regulation of kappa receptor subtypes (34) makes it difficult to identify the ingestive behavior is we:11 established (5,22,25).
    [Show full text]
  • PRODUCT INFORMATION Spinorphin Item No
    PRODUCT INFORMATION Spinorphin Item No. 29914 NH CAS Registry No.: 137201-62-8 Formal Name: L-leucyl-L-valyl-L-valyl-L-tyrosyl-L- O H O N prolyl-L-tryptophyl-L-threonine N OH O N H Synonyms: Leu-Val-Val-Tyr-Pro-Trp-Thr, O OH H LVVYPWT O O N MF: C45H64N8O10 N N O FW: 877.0 H H NH2 Purity: ≥95% UV/Vis.: λmax: 222 nm Supplied as: A crystalline solid Storage: -20°C OH Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Spinorphin is supplied as a crystalline solid. A stock solution may be made by dissolving the spinorphin in the solvent of choice, which should be purged with an inert gas. Spinorphin is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of spinorphin in these solvents is approximately 30 mg/ml. Description Spinorphin is a heptapeptide inhibitor of the enkephalin-degrading enzymes aminopeptidase, dipeptidyl aminopeptidase, angiotensin-converting enzyme (ACE), and enkephalinase (IC50s = 3.3, 1.4, 2.4, and 10 µg/ml, respectively, for monkey brain enzymes).1 It is selective for these enzymes over human serum aminopeptidase A (IC50 = >100 µg/ml), as well as porcine kidney aminopeptidase B, aminopeptidase M, dipeptidyl peptidase 1 (DPP-1), DPP-2, DPP-3, and DPP-4 (IC50s = >55 µg/ml for all). Spinorphin inhibits chemotaxis, production of reactive oxygen species (ROS), and exocytosis of glucuronidase and collagenase in polymorphonuclear neutrophils (PMNs). It potentiates enkephalin-induced action potentials in rat hippocampal slices.
    [Show full text]
  • Neprilysin Controls the Synaptic Activity of Neuropeptides in the Intercalated Cells of the Amygdala
    Molecular Pharmacology Fast Forward. Published on June 30, 2020 as DOI: 10.1124/mol.119.119370 This article has not been copyedited and formatted. The final version may differ from this version. Neprilysin controls the synaptic activity of neuropeptides in the intercalated cells of the amygdala Authors: Gregoriou GC, Patel SD, Winters BL, Bagley EE Primary laboratory of origin: Discipline of Pharmacology & Charles Perkins Centre, Charles Perkins Centre D17, Downloaded from University of Sydney, Camperdown, NSW, 2006, Australia. molpharm.aspetjournals.org at ASPET Journals on October 1, 2021 1 Molecular Pharmacology Fast Forward. Published on June 30, 2020 as DOI: 10.1124/mol.119.119370 This article has not been copyedited and formatted. The final version may differ from this version. Running title: Neuropeptides degradation in the amygdala Corresponding author: Elena Bagley Address: Discipline of Pharmacology & Charles Perkins Centre, Charles Perkins Centre D17, University of Sydney, Camperdown, NSW, 2006, Australia. Telephone: 61 2 93514895 Fax: N/A E-mail: [email protected] Number of pages: 31 Downloaded from Number of figures: 3 Number of references: 56 Words in abstract: 245 molpharm.aspetjournals.org Words in introduction: 486 Words in discussion: 844 Abbreviations: at ASPET Journals on October 1, 2021 ACE: angiotensin-converting enzyme ACSF: artificial cerebrospinal fluid APN: aminopeptidase N BLA: basolateral amygdala CNS: central nervous system DOR: δ-opioid receptor EPSC: excitatory post‐synaptic currents MOR: µ-opioid receptor met-enk: methione enkephalin NEP: neprilysin N/OFQ: Nociceptin/Orphanin FQ PI: peptidase inhibitors PPR: paired pulse ratio 2 Molecular Pharmacology Fast Forward. Published on June 30, 2020 as DOI: 10.1124/mol.119.119370 This article has not been copyedited and formatted.
    [Show full text]
  • Opioid Receptors in Immune and Glial Cells—Implications for Pain Control
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Institutional Repository of the Freie Universität Berlin REVIEW published: 04 March 2020 doi: 10.3389/fimmu.2020.00300 Opioid Receptors in Immune and Glial Cells—Implications for Pain Control Halina Machelska* and Melih Ö. Celik Department of Experimental Anesthesiology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany Opioid receptors comprise µ (MOP), δ (DOP), κ (KOP), and nociceptin/orphanin FQ (NOP) receptors. Opioids are agonists of MOP, DOP, and KOP receptors, whereas nociceptin/orphanin FQ (N/OFQ) is an agonist of NOP receptors. Activation of all four opioid receptors in neurons can induce analgesia in animal models, but the most clinically relevant are MOP receptor agonists (e.g., morphine, fentanyl). Opioids can also affect the function of immune cells, and their actions in relation to immunosuppression and infections have been widely discussed. Here, we analyze the expression and the role of opioid receptors in peripheral immune cells and glia in the modulation of pain. All four opioid receptors have been identified at the mRNA and protein levels in Edited by: immune cells (lymphocytes, granulocytes, monocytes, macrophages) in humans, rhesus Sabita Roy, monkeys, rats or mice. Activation of leukocyte MOP, DOP, and KOP receptors was University of Miami, United States recently reported to attenuate pain after nerve injury in mice. This involved intracellular Reviewed by: 2+ Lawrence Toll, Ca -regulated release of opioid peptides from immune cells, which subsequently Florida Atlantic University, activated MOP, DOP, and KOP receptors on peripheral neurons.
    [Show full text]
  • Changes in Spinal and Opioid Systems in Mice Deficient in The
    The Journal of Neuroscience, November 1, 2002, 22(21):9210–9220 Changes in Spinal ␦ and ␬ Opioid Systems in Mice Deficient in the A2A Receptor Gene Alexis Bailey,1 Catherine Ledent,2 Mary Kelly,1 Susanna M. O. Hourani,1 and Ian Kitchen1 1Pharmacology Group, School of Biomedical and Life Sciences, University of Surrey, Guildford, Surrey, GU2 7XH United Kingdom, and 2Institut de Recherche Interdisciplinaire en Biologie Humaine et Nucle´ aire, Universite´ Libre de Bruxelles, B-1070 Brussels, Belgium A large body of evidence indicates important interactions be- but not in the brains of the knock-out mice. ␮ and ORL1 receptor tween the adenosine and opioid systems in regulating pain at both expression were not altered significantly. Moreover, a significant ␦ the spinal and supraspinal level. Mice lacking the A2A receptor reduction in -mediated antinociception and a significant increase gene have been developed successfully, and these animals were in ␬-mediated antinociception were detected in mutant mice, shown to be hypoalgesic. To investigate whether there are any whereas ␮-mediated antinociception was unaffected. Comparison compensatory alterations in opioid systems in mutant animals, we of basal nociceptive latencies showed a significant hypoalgesia in have performed quantitative autoradiographic mapping of ␮, ␦, ␬, knock-out mice when tested at 55°C but not at 52°C. The results and opioid receptor-like (ORL1) opioid receptors in the brains and suggest a functional interaction between the spinal ␦ and ␬ opioid spinal cords of wild-type and homozygous A2A receptor knock- and the peripheral adenosine system in the control of pain out mice. In addition, ␮-, ␦-, and ␬Ϫmediated antinociception pathways. using the tail immersion test was tested in wild-type and homozy- ␮ ␦ gous A2A receptor knock-out mice.
    [Show full text]
  • Drugs of Abuseon September Archived 13-10048 No
    U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WWW.DEA.GOV 9, 2014 on September archived 13-10048 No. v. Stewart, in U.S. cited Drugs of2011 Abuse EDITION A DEA RESOURCE GUIDE V. Narcotics WHAT ARE NARCOTICS? Also known as “opioids,” the term "narcotic" comes from the Greek word for “stupor” and originally referred to a variety of substances that dulled the senses and relieved pain. Though some people still refer to all drugs as “narcot- ics,” today “narcotic” refers to opium, opium derivatives, and their semi-synthetic substitutes. A more current term for these drugs, with less uncertainty regarding its meaning, is “opioid.” Examples include the illicit drug heroin and pharmaceutical drugs like OxyContin®, Vicodin®, codeine, morphine, methadone and fentanyl. WHAT IS THEIR ORIGIN? The poppy papaver somniferum is the source for all natural opioids, whereas synthetic opioids are made entirely in a lab and include meperidine, fentanyl, and methadone. Semi-synthetic opioids are synthesized from naturally occurring opium products, such as morphine and codeine, and include heroin, oxycodone, hydrocodone, and hydromorphone. Teens can obtain narcotics from friends, family members, medicine cabinets, pharmacies, nursing 2014 homes, hospitals, hospices, doctors, and the Internet. 9, on September archived 13-10048 No. v. Stewart, in U.S. cited What are common street names? Street names for various narcotics/opioids include: ➔ Hillbilly Heroin, Lean or Purple Drank, OC, Ox, Oxy, Oxycotton, Sippin Syrup What are their forms? Narcotics/opioids come in various forms including: ➔ T ablets, capsules, skin patches, powder, chunks in varying colors (from white to shades of brown and black), liquid form for oral use and injection, syrups, suppositories, lollipops How are they abused? ➔ Narcotics/opioids can be swallowed, smoked, sniffed, or injected.
    [Show full text]
  • Morphine Indiscriminatingly Overstimulates All Opioid Receptors Including Those Not Involved in (Morphine) Pain Control (Exogenous)
    Extensions des propriétés des inhibiteurs mixtes des enképhalinases aux douleurs de la sphère cranio-faciale. Nouvelles applications à la migraine et aux douleurs de la cornée. Bernard P. Roques Professeur Emérite, Université Paris Descartes Unité 1267 Inserm, 4 avenue de l’Observatoire, 75006 Paris. ATHS Biarritz, 1-4 Octobre 2019 CONFIDENTIAL 1 Endorphins and their receptors. Endomorphin-1 Tyr – Pro – Trp – Phe – NH2 Endomorphin-2 Tyr – Pro – Phe – Phe – NH2 2 2 Drug Discovery : designing the ideal opioid (From B.L. Kieffer, Nature (2016), 537, 170-171) 3 Three levels of pain control by endogenous opioid system (EOS) EOS EOS Attacking pain at EOS its source Relieving or reducing pain at its source More than 50% of MO effects are attributable to peripheral neurons (nociceptors) Roques, B.P., Fournié-Zaluski, M.C. and Wurm, M., Nature Reviews Drug Discovery, 2012 4 DENKIs: mechanism of action The endogenous opioid system (EOS) is present at all levels of physiological-nociceptive control i.e. periphery, spinal cord and brain Elements of the EOS are opioid receptors, enkephalins and their inactivating enzymes Dual Inhibitors of ENKephalinases (DENKIs) potentiate physiological functions of DENKI enkephalins (e.g. pain control) only on those pathways where they are tonically released Enkephalinases APN NEP No adverse effects Enkephalins Y G G F M(L) (endogenous) Opioid receptors Morphine indiscriminatingly overstimulates all opioid receptors including those not involved in (Morphine) pain control (exogenous) Adverse effects 5 Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets in a murine model of bone cancer-induced pain.
    [Show full text]